Patents by Inventor Marc Trombe

Marc Trombe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS METHOD
    Publication number: 20140030265
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: June 28, 2013
    Publication date: January 30, 2014
    Applicant: AVENTIS PHARMA SA
    Inventors: Francis BLANCHE, Béatrice CAMERON, Sylvie SORDELLO, Céline NICOLAZZI, Marc TROMBE, Mark NESBIT
  • Modified soluble FGF receptor Fc fusions method
    Patent number: 8481487
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: July 9, 2013
    Assignee: Aventis Pharma S.A.
    Inventors: Francis Blanche, Béatrice Cameron, Sylvie Sordello, Céline Nicolazzi, Marc Trombe, Mark Nesbit
  • MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WITH IMPROVED BIOLOGICAL ACTIVITY
    Publication number: 20120195851
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: January 11, 2012
    Publication date: August 2, 2012
    Applicant: AVENTIS PHARMA SA
    Inventors: Francis BLANCHE, Beatrice CAMERON, Mark NESBIT, Sylvie SORDELLO, Celine NICOLAZZI, Marc TROMBE
  • Modified soluble FGF receptor Fc fusions with improved biological activity
    Patent number: 8119770
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: February 21, 2012
    Assignee: Aventis Pharma SA
    Inventors: Francis Blanche, Beatrice Cameron, Mark Nesbit, Sylvie Sordello, Celine Nicolazzi, Marc Trombe
  • MODIFIED SOLUBLE FGF RECEPTOR FC FUSIONS WSITH IMPROVED BIOLOGICAL ACTIVITY
    Publication number: 20100061979
    Abstract: The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.
    Type: Application
    Filed: November 22, 2007
    Publication date: March 11, 2010
    Applicant: CENTELION
    Inventors: Francis Blanche, Beatrice Cameron, Mark Nesbit, Sylvie Sordello, Celine Nicolazzi, Marc Trombe